NCT00526877View on ClinicalTrials.gov

An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions

SchizophreniaSchizoaffective Disorders

Interventions

DRUG

Risperidone

Risperidone long-acting injectable 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 24 weeks.